Latham & Watkins Advises on Beta Bionics’ Upsized US$204 Million Initial Public Offering

Beta Bionics, Inc., a pioneering leader in the development of advanced diabetes management solutions, has announced the pricing of its upsized initial public offering of 12,000,000 shares of common stock at a price to the public of US$17 per share. The gross proceeds to Beta Bionics from the offering, before deducting underwriting discounts and commissions and offering expenses payable by Beta Bionics, are expected to be US$204 million. In addition, the underwriters have a 30-day option to purchase up to an additional 1,800,000 shares of common stock at the public offering price, less underwriting discounts and commissions, consisting of 475,000 shares from Beta Bionics and 1,325,000 shares from the selling stockholders named in the prospectus. Beta Bionics will not receive any proceeds from any sale of shares by the selling stockholders.

Latham & Watkins LLP is advising the underwriters in the offering with a capital markets team led by New York partner Nathan Ajiashvili and Orange County/Bay Area partner Ross McAloon, with associates Zoey Wu and Caitlin Nguyen.